Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Conference Coverage

Vepdegestrant Plus Palbociclib for Patients With ER-Positive, HER2-Negative Advanced Breast Cancer

Featuring Seth Wander, MD, PhD

 

Seth Wander, MD, PhD, Massachusetts General Hospital, discussed results from the phase 1b cohort of a phase 1/2 clinical trial which demonstrated that vepdegestrant plus palbociclib is clinically effective among patients with heavily pretreated, ER-positive, HER2-negative advanced breast cancer. 

These results were first reported at the 2023 San Antonio Breast Cancer Symposium. 


Source: 

Hamilton E, Jeselsohn R, Hurvitz S, et al. Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib in ER–positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: phase 1b cohort. Presented at the 2023 San Antonio Breast Cancer Symposium; December 5-9; San Antonio, Texas. Abstract PS15-03 

© 2023 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates. 

Advertisement

Advertisement

Advertisement

Advertisement